Printer Friendly
The Free Library
4,468,374 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

Astellas Pharma, Ferring Pharmaceuticals Sign Licensing Agreement for Degarelix, Prostate Cancer Agent.


Tokyo, Japan, Feb 1, 2006 - (JCN) - Astellas Pharma announced n January 31 that it has signed a licensing agreement with Ferring Pharmaceuticals on degarelix, Ferring's proprietary agent for treating prostate cancer.

Under the agreement terms, Astellas Pharma will be licensed to exclusively develop and market the agent in Japan. Accordingly, Astellas will make upfront and milestone payments as well as royalties on product sales to Ferring Pharmaceuticals.

Degarelix, a gonadotropin chorionic gonadotropin , human chorionic gonadotropin (HCG) (hCG) a glycopeptide hormone produced by the fetal placenta syncytiotrophoblasts that maintains the function of the corpus luteum during the first few weeks of pregnancy; the basis for most commonly used pregnancy tests. It is used pharmaceutically to treat certain cases of cryptorchidism and male infertility, to induce ovulation and pregnancy in certain infertile, anovulatory women, and to stimulate oocyte releasing hormone (GnRH GnRH
abbr.
gonadotropin-releasing hormone
) receptor antagonist, helps suppress the testosterone secretion so that it can inhibit the growth of prostate cancer.

Copyright [c] 2006 Japan Corporate News Network. All rights reserved.
COPYRIGHT 2006 Japan Corporate News Network K.K.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2006, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:JCNN News Summaries
Date:Feb 2, 2006
Words:100
Previous Article:RIKEN Elucidates Inactivation Mechanism of Gibberellin, Plant Growth-promoting Hormone.
Next Article:Goldwin to Market Pollen Shield, Anti-hay Fever Cloths.



Related Articles
Astellas Pharma, MerLion Pharmaceuticals Sign Joint Research Agreement for Naturally-derived Drug Candidate Search.
Astellas Pharma, Theravance to Enter into Licensing Agreement for Investigational Antibiotic Telavancin.
Astellas Pharma Sues Toyo Pharmar and Aska Pharmaceutical for Patent Infringement.
Astellas Pharma, Toyama Chemical Agree on Joint Development of Quinolone Antibiotic T-3811 in Japan.
Astellas and Toyama Chemical Announce Basic Licensing Agreement on Domestic Marketing and Joint Development of Quinolone Antibiotic T-3811.
Astellas Establishes New Subsidiary 'Astellas Pharma Chemicals Co., Ltd.'.
Ilypsa and Astellas Enter a Licensing Agreement on ILY101 for Treatment of Hyperphosphatemia in Japan.
Astellas Pharma, FibroGen Conclude Licensing Agreement for Oral Anemia Treatments.
Astellas Discontinues Development of Immunosuppressant FK778.
Kirin and Astellas Enter Into Licensing Agreement on Immunosuppressive Fully Human Monoclonal Antibody.

Terms of use | Copyright © 2008 Farlex, Inc. | Feedback | For webmasters | Submit articles